The effect of intravenous L-carnitine treatment on hemodialysis patients

The effect of intravenous L-carnitine treatment on hemodialysis patients - The effect of intravenous L-carnitine treatment on hemodialysis patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011208

Enrollment

Registered

2013-07-31

Start date

2013-08-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD(hemodialysis patients)

Interventions

1) Intravenous L-carintine infusion at the end of each hemodialysis session (20mg/kg, 6 months) 2) wash out (about 3 months) 3) Intravenous saline infusion at the end of each hemodialysis (6 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CKD(hemodialysis patients)

Exclusion criteria

Exclusion criteria: 1) Under treatment for malignancy and severe infection 2) In pregnancy and lactating 3) Severe allergic reaction for L-carnitine

Design outcomes

Primary

Measure	Time frame
improvement of anemia, cardiac function, and muscle wasting (after 6 month-administration)	—

Countries

Japan

Contacts

Public ContactJUN INO

Toda Central General Hospital Department of Nephrology

pikkun46@hotmail.com048-442-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026